{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T18:38:02.856457",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 43,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "prolonged survival",
        "event-free survival",
        "eventless survival",
        "quality-adjusted life years (QALYs)",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "overall response rate",
        "response rate",
        "disease control rate",
        "time to response",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "symptom control"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse drug reactions",
        "side effects",
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "serious undesirable effects",
        "serious side effects on the skin",
        "treatment-related disutility for intravenous administration",
        "mortality-related toxicity",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "serious undesirable effects",
        "serious side effects on the skin",
        "mortality-related toxicity"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "health status",
        "health-related quality of life",
        "health-related quality of life measured by time to death",
        "quality of life",
        "overall health status",
        "preservation of quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost per QALY"
      ],
      "utilities": [
        "utility decrement per cycle of treatment"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}